2023
HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience
Podany P, Golastani R, Zhan H, Liang Y, Harigopal M, Krishnamurti U. HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience. American Journal Of Clinical Pathology 2023, 160: s9-s10. DOI: 10.1093/ajcp/aqad150.021.Peer-Reviewed Original ResearchLow HER2 expressionInvasive breast carcinomaIHC scoreHER2 expressionGroup 1Group 3HER2 immunohistochemistryHER2 testingGroup 2HER2 FISHGroup 4ASCO/CAP guidelinesGroup 5Single institutional experienceRecent clinical trialsStandard of careASCO/CAP 2018 guidelinesHER2/CEP17 ratioEquivocal HER2HER2 positivityTrastuzumab deruxtecanMore patientsCAP guidelinesPatient eligibilityCase report
2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapy